It’s ASH week! In four days, hematologists, oncologists, researchers and reporters from all over the world will converge on Orlando, Florida’s International Drive to share the latest developments involving blood related disorders at the annual American Society of Hematology meetings. I will be in Orlando Thursday getting ready for the weekend’s meetings as well.
The pre-ASH press releases are flowing in. Here is part of a release from a smaller biopharmaceutical company, Zalicus:
Nov. 29, 2010
Zalicus to Present Data on Novel A2A Agonist Oncology Program at the American Society for Hematology Meeting
– Novel Synergistic Mechanism Discovered for the Treatment of Multiple Myeloma and Other B-cell Cancers Using Zalicus cHTS Technology –
CAMBRIDGE, Mass., Nov 29, 2010 Zalicus Inc. announced today that preclinical data on its discovery of novel A2A agonist oncology programs for the treatment of multiple myeloma and other B-cell malignancies will be highlighted at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL on December 4-7, 2010.
“These data reinforce the rationale for investigation of A2A agonists in the treatment of multiple myeloma and other B-cell malignancies and highlight the power of the Zalicus combination high throughput screening (cHTS(TM)) technology to interrogate combination activity across large panels of cancer cells to identify novel mechanisms for therapeutic application,” commented Mark H.N. Corrigan, M.D., President and CEO of Zalicus Inc. “Zalicus is continuing to leverage the power of its proprietary cHTS technology through research collaborations with biopharmaceutical companies such as our ongoing oncology research collaborations with Clinical Data, Inc. and Novartis.”
Sunday, December 5, 2010, 6:00-8:00 p.m., Poster session I: Myeloma — Pathophysiology and Preclinical Studies, excluding Therapy. #2990, Poster Board II-870, “ATL313, A Potent, and Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma”, Rickles, et al, Orange County Convention Center, Hall A3/A4.
ATL313 is a potent and selective A2A agonist being evaluated by Zalicus and PGxHealth, LLC, a division of Clinical Data, Inc., for the treatment of B-cell cancers, including multiple myeloma. ATL313 is also being evaluated by Clinical Data, Inc. and its other collaborators for a number of indications including glaucoma, chronic pain, multiple sclerosis and atherosclerosis.
The release release mentions something called a poster session on Sunday. These poster sessions are just that–rooms full of enlarged research study abstracts.
Sometimes research studies are deemed important enough to be given presentation time as well. These are called break-out sessions. Studies which are deemed most groundbreaking or newsworthy are singled-out to be presented and discussed in larger meetings–sometimes with thousands listening on.
Note this release is announcing results of a pre-clinical study. This usually means actual patients have yet to be involved.
I have not researched the importance of ATL313. I will learn more about what Zalicus does–and why that may or may not be important to us as myeloma patients–as the meetings move forward. The same goes for dozens of other multiple myeloma related presentations which will be made throughout the upcoming weekend.
Feel good and keep smiling! Pat